Published ahead of print on September 15, 2005, doi:10.1164/rccm.200503-425OC
© 2006 American Thoracic Society doi: 10.1164/rccm.200503-425OC
Imbalance between Cysteine Proteases and Inhibitors in a Baboon Model of Bronchopulmonary DysplasiaDivision of Newborn Medicine, Children's Hospital, Harvard Medical School; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Departments of Pediatrics and Pathology, Vanderbilt University Medical Center, Nashville, Tennessee; Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri; Department of Oral and Biological Sciences, University of British Columbia, Vancouver, British Columbia, Canada; and Institute of Physiological Chemistry, Martin Luther University Halle-Wittenberg, Halle, Germany Correspondence and requests for reprints should be addressed to Sule Cataltepe, M.D., Division of Newborn Medicine, Children's Hospital, Enders 950, 300 Longwood Avenue, Boston, MA 02115. E-mail: sule.cataltepe{at}childrens.harvard.edu
Rationale: Bronchopulmonary dysplasia (BPD) continues to be a major morbidity in preterm infants. The lung pathology in BPD is characterized by impaired alveolar and capillary development. An imbalance between proteases and protease inhibitors in association with changes in lung elastic fibers has been implicated in the pathogenesis of BPD. Objective: To investigate the expression and activity levels of papain-like lysosomal cysteine proteases, cathepsins B, H, K, L, S, and their inhibitors, cystatins B and C, in a baboon model of BPD. Methods: Real-time reverse transcriptase–polymerase chain reaction, immunohistochemistry, immunoblotting, active site labeling of cysteine proteases, and in situ hybridization were performed. Measurements and Main Results: The steady-state mRNA and protein levels of all cathepsins were significantly increased in the lung tissue of baboons with BPD. In contrast, the steady-state mRNA and protein levels of two major cysteine protease inhibitors, cystatin B and C, were unchanged. Correlating with these alterations, the activity of cysteine proteases in lung tissue homogenates and bronchoalveolar lavage fluid was significantly higher in the BPD group. The levels of cathepsin B, H, and S increased and cathepsin K decreased with advancing gestation. All cathepsins, except for cat K, were immunolocalized to macrophages in BPD. In addition, cathepsin H and cystatin B were colocalized in type 2 alveolar epithelial cells. Cathepsin L was detected in some bronchial epithelial, endothelial, and interstitial cells. Cathepsin K was localized to some perivascular cells by in situ hybridization. Conclusions: Cumulatively, these findings demonstrate an imbalance between cysteine proteases and their inhibitors in BPD.
Key Words: baboon • bronchopulmonary dysplasia • cathepsin • macrophage • protease Bronchopulmonary dysplasia (BPD) was originally described in 1967 as a chronic pulmonary disease that developed in premature infants who were treated with prolonged ventilation and 80 to 100% O2 (1). The lung pathology in classic BPD was characterized by widespread bronchial and bronchiolar disease with fibroproliferative changes, smooth muscle hyperplasia, and alternating areas of emphysema with atelectasis (1, 2). Since the original description of BPD, major advances in neonatology have significantly improved the care and survival rates of very low birth weight infants (birth weight < 1,500 g). Despite these advances, a milder form of the classic BPD, "new BPD," continues to be a significant morbidity of premature infants (3, 4). Lung pathology in new BPD is markedly different than in the old BPD and is primarily characterized by impaired alveolar and capillary development (5). Approximately 25 to 30% of very low birth weight infants develop the new BPD (6, 7). Subsequently, these infants are more likely to have impaired growth, abnormal neurodevelopment, reactive airway disease, and respiratory infections requiring hospitalization (8–10). The pathogenesis of BPD is multifactorial and incompletely understood. Lung immaturity, barotrauma/volutrauma, oxygen toxicity, and inflammation are well-recognized risk factors (3, 11, 12). An imbalance between proteases and protease inhibitors also has been implicated in the pathogenesis of BPD (12). Numerous studies in human infants with the classic BPD have shown increased elastase and decreased elastase inhibitory activity in the airway secretions (13–16). Elastin, the target molecule of elastolytic enzymes, is an important structural component of the lung. In elastin-deficient mice, impaired terminal airway branching is accompanied by fewer and dilated distal air sacs (17). Abnormal patterns of elastin expression and accumulation are observed in baboon and lamb models of BPD as well as in autopsy specimens of infants who died of BPD (16, 18–21). Thus far, studies that investigated protease–antiprotease imbalance in BPD have focused on two groups of elastolytic proteases: serine proteases, such as neutrophil elastase (NE) and trypsin (15, 22), and metalloproteinases (MMPs), such as MMP-2 and MMP-9 (23, 24). Recently, a third group of proteases, the papain family of cysteine proteases, has been implicated in the pathogenesis of lung disorders (25). These proteases, cathepsins (cat) B, H, K, L, and S, play important roles in diverse processes, some of which are relevant to the pathophysiology of BPD, such as fibrosis (26), apoptosis (27), and extracellular matrix remodeling (28, 29). We therefore hypothesized that cysteine proteases have a role in the development of BPD. As the first step toward exploring this hypothesis, we characterized the mRNA and protein expression and cellular distribution of cat B, H, K, L, and S, and two of their major inhibitors, cystatin B and C, and determined the activity of cathepsins in a well-characterized baboon model of BPD (30). The ontogeny of cathepsins and cystatins in the baboon lung between 125 and 185 d gestation was also characterized. Our findings demonstrate an imbalance between cysteine proteases and their inhibitors in BPD. Some of the results of this study have been reported in the form of an abstract (31).
Animal Model Frozen and paraffin-embedded baboon lung tissues and necropsy bronchoalveolar lavage (BAL) samples were provided by the Southwest Foundation for Biomedical Research (San Antonio, TX). All procedures were approved by the Institutional Animal Care and Use Committee at the Southwest Foundation for Biomedical Research. Details of the model have been described previously (30). Briefly, baboons that were delivered by hysterotomy at 125 d developed characteristic features of the new BPD after surfactant (Survanta; Ross, Columbus, OH) replacement, mechanical ventilation, and "as needed" oxygen treatment for 14 d (BPD group). Baboons that were delivered at 125 or 140 d and killed immediately served as the gestational control (GC) animals (125- or 140-d groups). Another control group consisted of baboons that were born via natural delivery (ND) at full-term gestation (  185 d) and killed 2 to 3 d later.
Isolation of Total RNA and Reverse Transcription
Real-Time Polymerase Chain Reaction Analysis
Antibodies
Immunoblotting
Active Site Labeling of Cysteine Proteases and Immunoprecipitation
Immunohistochemistry
In Situ Hybridization
Statistical Analysis
Steady-State mRNA Levels of Cysteine Proteases and Cystatins in BPD Steady-state mRNA levels of cat B, H, K, L, and S, and cystatin B and C were analyzed by real-time PCR after reverse transcription of total RNA isolated from fresh frozen baboon lung tissues (Figure 1). In BPD, the steady-state mRNA levels of cat B, H, K, L, and S were increased about 1.5, 2.5, 9, 2.5, and 3 times, respectively, in comparison to the 140-d GC group (p < 0.05). Cat K, L, and S mRNA levels in BPD were also significantly higher than in the ND group (66-, 2.8-, and 1.9-fold, respectively; p < 0.05). The steady-state mRNA levels of cat B, H, and S were significantly higher in the full-term lungs (ND group) than in the 125-d GC group, whereas the cat S mRNA level was significantly lower in the ND group than in the 125-d GC group. In contrast to the alterations observed in cysteine proteases, the steady-state mRNA levels of cystatin B and C were similar in all GC groups as well as in the BPD group (Figure 1).
Cysteine Protease and Cystatin Protein Expression in BPD To characterize the expression pattern of cat B, H, K, L, and S, and cystatin B and C at the protein level, baboon lung lysates were analyzed by immunoblotting and densitometry (Figure 2). In BPD, cat B, H, K, L, and S proteins were increased about 2, 25, 2.5, 2, and 18 times, respectively, in comparison to the 140-d GC group (p < 0.05). Parallel with the alterations observed at the mRNA level, cat K, L, and S protein levels were also significantly higher in the BPD samples in comparison to the ND group (15, 2.2, and 3.4 times, respectively; p < 0.05). During lung development between 125-d and full-term gestation, the expression level of cat B, H, and S proteins increased and cat K decreased significantly, whereas that of cat L was similar in all GC groups. The protein levels of cystatin B and C, a major intracellular and a secreted inhibitor of cystein proteases, respectively, were similar in all groups. Similar results were obtained when samples were normalized to either total protein (i.e., same amount of total protein was loaded per lane on each gel) or  -actin (data not shown). Proenzyme forms of cathepsin B, L, and S were detected in some samples, but there was no statistically significant difference among the study groups. Cat H was detected in both single- and heavy-chain forms in ND and BPD groups. In all samples, densitometry was performed using only the mature single-chain form of the enzymes.
Cysteine Protease Activity in BPD To determine if the activity of cathepsins showed a parallel increase to the levels of these proteins in the lung tissues and BALF, active site labeling of cysteine proteases was performed in 140-d, ND, and BPD group samples (Figure 3). Both in lung tissues (Figure 3A) and BALF (Figure 3B), there was increased activity of cysteine proteases in BPD relative to both the 140-d and ND controls. The individual cathepsins that contributed to the total cysteine protease activity in BPD samples were determined by immunoprecipitation of active site–labeled lung homogenates using their specific antibodies (Figure 3C).
Detection of Cysteine Proteases and Cystatins in BALF To determine if active forms of cysteine proteases can be detected in BALF samples of baboons with BPD and to determine their relative levels, BALF samples were analyzed by immunoblotting and densitometry (Figure 4). Single-chain active forms of cat B and L enzymes were detected in BALF of 140-d and ND samples as well as the BPD samples. Cat B was also detected as a proenzyme in some ND and BPD samples. In BPD, the cat B level was similar to that in the ND group, but significantly higher than in the 140-d GC group, whereas the cat L level was significantly increased in comparison to both the 140-d and ND groups (p < 0.05). Interestingly, cat S was present only as a proenzyme in the 140-d group and as a single-chain enzyme (the only mature form of cat S) in the ND and BPD groups. By densitometry, the BALF cat S level was about three times higher in the BPD group than in the ND group. In overexposed immunoblots, small amounts of pro-cat H was detected in the 140-d samples, whereas ND and BPD groups had single-chain cat H (data not shown). Cat K was not detectable in BALF samples of either the BPD group or the GC groups. Both cystatins B and C were detectable in BALF in all groups tested in similar levels.
Macrophages in the 125-d Baboon Model of BPD Macrophages are the primary sources of several cathepsins. To determine if increased cathepsin levels were associated with an increased number of macrophages in the 125-d baboon model of BPD, we analyzed the mRNA expression of the macrophage marker CD68 in the lung tissue and BALF cell pellets by quantitative reverse transcriptase–PCR. In addition, BALF total and differential cell counts were performed on cytospin preparations. In the lung tissue, the steady-state mRNA level of CD-68 was significantly higher in the BPD group in comparison to 140-d GCs (Figure 5A; p < 0.05). The ND group was used as the control group for CD68 expression in BALF cells because the 140-d group had very few cells and RNA isolation was not successful. The BPD group had an approximate 3.5-fold increase in CD68 mRNA expression in comparison to the ND group (Figure 5B; p < 0.05). Absolute macrophage counts in BAL were increased about 10 and 2 times, respectively, in comparison to the 140-d and ND groups (Figure 5C; p < 0.05). The expression of CD68 at the protein level was determined semiquantitatively by immunohistochemistry using an anti-CD68 antibody in paraffin-embedded lung tissue sections of 140-d (Figure 5D), ND (Figure 5E), and BPD (Figure 5F) groups.
Immunolocalization of Cathepsins and Cystatin B in BPD To characterize the cellular distribution of cathepsins and the intracellular cysteine protease inhibitor cystatin B in BPD, immunohistochemistry was performed on paraffin-embedded baboon lung tissue sections using specific antibodies (Figure 6). Pro-surfactant protein C (pro-SPC) and CD68 were used as markers for type 2 alveolar epithelial cells and macrophages, respectively. Cat B was detected in macrophages and some CD68-negative interstitial cells (Figures 6A–6C). Some of these interstitial cells were identified as fibroblasts on the basis of their morphology (Figures 6B and 6C). Cat H protein was detected in type 2 alveolar epithelial cells in addition to macrophages (Figures 6D–6F). Type 2 cells were identified on the basis of their reactivity with pro-SPC antibody in serial sections (shown in the online supplement). Cat L was detected in CD68-positive cells (Figure 6G) as well as in some CD68-negative interstitial cells, some of which were fibroblasts (Figure 6J). In the ciliated, pseudostratified bronchial epithelium, cat L was detected in a supranuclear, apical localization (Figure 6H). Cat L immunoreactivity was also detected in some vascular and lymphoid endothelial cells in a subset of BPD samples (Figures 6I and 6J). Cat S expression was restricted to CD68-positive cells (Figures 6K and 6L). Cystatin B immunoreactivity was detected in macrophages, type 2 alveolar epithelial cells, as well as large airway epithelial cells (Figures 6M and 6N). Mouse (Figure 6O) and rabbit (not shown) primary antibody isotype controls did not show any immunoreactivity with the baboon lung tissues.
Cat K mRNA Detection in BPD by In Situ Hybridization The lung tissue distribution of cat K protein could not be reliably determined by immunohistochemistry due to poor reactivity of the antibodies with lung tissue sections of the BPD group baboons. To determine the mRNA distribution of cat K in baboon lung tissues in BPD, in situ hybridization was performed. Cathepsin mRNA was localized to some cells in the perivascular areas (Figure 7).
This study has shown the following in a baboon model of new BPD: (1) the cysteine proteases cat B, H, K, L, and S were up-regulated at the mRNA and protein levels in the lung; (2) cat B, H, L, and S protein levels were increased in the necropsy BALF samples; (3) the levels of two major inhibitors of cysteine proteases, cystatin B and C, in the lung and BALF were similar in BPD and control tissues; (4) increased activity of cat B, H, K, L, and S proteins were detected in lung tissue and BALF by active site labeling; (5) CD68-positive cells were increased both in the lung tissue and the airways; (6) cat B, H, L, and S, and cystatin B were expressed in CD68-positive cells in BPD. In addition, cat H and cystatin B were colocalized in type 2 alveolar epithelial cells, whereas cat L was detected in some bronchial epithelial and endothelial cells. Cat B and L immunoreactivity was detected in some CD68-negative interstitial cells, some of which were fibroblasts. Cat K mRNA was expressed in some cells that were localized to perivascular areas. Cumulatively, these findings demonstrate an imbalance between cysteine proteases and their inhibitors that results in an overall increase in cysteine protease activity in BPD. A second goal of this study was to examine the developmental changes in expression levels of cysteine proteases and cystatins. The expression levels of cat H and S were very low in the immature 125-d baboon lung and increased with advancing gestational age. Cat B levels also were higher in full-term animals than in the 125- or 140-d groups, whereas cat L, cystatin B, and cystatin C levels did not show any significant alterations between 125 and 185 d gestation. Interestingly, cat K levels decreased with advancing gestational age and were almost undetectable in the ND group. Consistent with a study by Buhling and coworkers (36), we did not detect any cat K immunoreactivity in either interstitial or alveolar macrophages. Instead, cat K was detected in mast cells in 125- and 140-d lung tissues by immunohistochemistry (S.C., unpublished data) and in some interstitial cells in perivascular locations, also likely mast cells, in BPD by in situ hybridization. Mast cell hyperplasia is a well-known feature of BPD (37, 38) and, taken together with our findings, this phenomenon can explain the source of increased cat K levels in BPD. Although cat K expression was previously reported in human bronchial and alveolar epithelial cells in one study (39), we could not confirm these findings in baboon lung tissues. Cat B, H, K, L, and S are members of the papain family of cysteine proteases (reviewed in References 25, 40). These proteases are synthesized in the endoplasmic reticulum as pre-proproteins and activated in the acidic environment of the lysosomes. Initially, the function of cathepsins was believed to be restricted to nonspecific degradation of proteins in the lysosomes. However, studies over the last decade have shown that, despite having some functional overlaps, cathepsins differ significantly in their substrate specificities, tissue distributions, and intracellular functions. For example, cat L and S play key roles in processing major histocompatibility complex class II–associated invariant chain in antigen-presenting cells (41, 42). Cat K, the major cysteine protease expressed in osteoclasts, has potent collagenolytic activity and plays a pivotal role in bone remodeling (43, 44). Cat H, a protease with both amino- and endoprotease activities, is involved in processing of SPB and SPC in type 2 alveolar epithelial cells (45, 46).
BPD is a unique disease of the immature lung that results in "disrupted lung development." However, several pathologic features, such as airway enlargement, inflammation, and fibrosis, are common findings in some adult lung diseases and BPD. Therefore, they may also share similar underlying mechanisms of lung injury. Although this is the first report to demonstrate an association between cysteine proteases and BPD, recent studies in genetically modified mice have suggested a role for cathepsins in the development of pathologic processes in the lung, such as fibrosis and emphysema. For example, overexpression of interleukin 13 or IFN-
This study showed that the expression levels and activities of cat B, H, K, L, and S were up-regulated in BPD. This finding does not necessarily imply that these cathepsins collectively function as mediators or protective molecules in BPD. For example, cat K, as indicated above, could have a protective role in the lung through its antifibrotic activity. In contrast, cat L is a potential candidate to function as a mediator of BPD. In addition to being a potent elastolytic protease, cat L can cleave and inactivate protective molecules in the lung, such as Although NE is regarded as the major proteinase responsible from tissue damage in old BPD, a paucity of literature on NE and its inhibitors in new BPD together with emerging data on other classes of proteases, such as cathepsins and MMPs, raise questions about the relative role of NE in new BPD. Sequential tracheal aspirate fluids of baboons with new BPD showed a higher number of macrophages than neutrophils at each time point tested, although this difference did not reach statistical significance because of the variability (30). We noted significantly increased number of macrophages in necropsy BALF samples in the same baboon model of BPD. On the basis of these findings, we propose that, in the surfactant era, the predominant inflammatory cell type in BPD has become the macrophage instead of the neutrophil. If our speculation is supported with data from human infants, then neutrophil to macrophage switch could account for the changing profile of proteases in new BPD. Another protease implicated in new BPD is MMP-9, which is secreted by both neutrophils and macrophages. However, it is intriguing that, although the imbalance between cysteine proteases and inhibitors in BPD is a consequence of increased levels of cysteine proteases, MMP-9–tissue inhibitor of metalloproteinase (TIMP) 1 imbalance is a consequence of decreased levels of the inhibitor TIMP-1 (24). With the exception of cat S, cathepsins have an acidic pH optimum and to maintain their activity extracellularly, they must be released into an acidic environment (25, 40, 52). An interesting finding of this study was the detection of mature and active forms of cat B, H, L, and S in BALF in BPD. Both pro and mature forms of cathepsins can be released from different cell types, including activated macrophages (cat B, L, S, K) (53, 54), smooth muscle cells (cat S) (55), and fibroblasts (cat B) (56). Furthermore, Punturieri and colleagues have shown that macrophages can acidify their pericellular space by using a vacuolar type H+-ATPase before releasing cathepsins (54). This important observation explains how extracellular cathepsins in BALF could maintain their activity in the airways, provided that they are released from certain cells, such as macrophages. Alternatively, detection of cathepsins in BALF may be due to release from detached and necrotic airway cells. Our study has some limitations that need to be considered. First, the sample size of the study groups is relatively small for statistical analysis. Second, cysteine protease activity levels are measured by active site labeling and could be affected by potential contribution of other cysteine proteases in addition to cat B, H, K, L, and S. Finally, cysteine protease and cystatin measurements in BALF were performed by normalizing the samples to total protein in BALF. This method could give rise to inaccurate results in the presence of capillary leakage, such as that occurs in BPD. Nevertheless, the magnitude of differences observed in BALF cathepsins were unlikely to be affected by any biases introduced by normalization methods and were also consistent with the tissue levels. In summary, we have shown significant increases in cat B, H, K, L, and S mRNA and protein levels in association with increased activities of these enzymes in the lung tissues of baboons with BPD. The increased levels of cathepsins accompany an influx of macrophages in the lung tissue and airways in BPD. In addition to macrophages, cathepsins are expressed in several different cell types in BPD. Cumulatively, these results suggest that cysteine proteases may play a role in the development of BPD. Considering the diverse functions of these proteases, it is possible that they could also have differential roles in the pathogenesis of BPD. Further studies are required to define the specific roles of cysteine proteases in the lung and to determine whether inhibition of any cathepsin(s) could ameliorate pathologic findings associated with BPD.
The authors thank all the personnel at the Bronchopulmonary Dysplasia Resource Center in San Antonio for their work related to the baboon model. They also thank Dr. Steve D. Shapiro for critical review of the manuscript and helpful suggestions; Drs. Gary A. Silverman, Thomas Mariani, Mark Exley, Helen Christou, Don McCurnin, and Harry Kozakewich for valuable discussions; and Rita Medek for excellent technical support.
Supported by National Institutes of Health grants HL075904 (S.C.), HL04403 (S.C.), HL63387 (R.A.P.), and P51 RR13986 for facility support; Survanta was donated by Ross Laboratories, Columbus, Ohio, and ventilators were donated by InfantStar (Infrasonics, San Diego, CA). This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Originally Published in Press as DOI: 10.1164/rccm.200503-425OC on September 15, 2005 Conflict of Interest Statement: None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Received in original form March 17, 2005; accepted in final form September 14, 2005
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOP
ABSTRACT
METHODS
in the adult murine lung causes emphysema and inflammation that are accompanied by induction of several cathepsins in addition to MMPs (
1-antitrypsin, secretory leukocyte protease inhibitor, and defensins (
